SNS Insider Unveils Strategic Insights into the U.S. Androgenetic Alopecia Market’s Rapid Expansion—Valued at USD 0.84 Billion in 2023—As the Region Eyes a USD 1.67 Billion Milestone by 2032 Amid Surging Demand for Gender-Specific Solutions.
Austin, June 19, 2025 (GLOBE NEWSWIRE) — Androgenetic Alopecia Market Size & Growth Analysis
“According to SNS Insider, the Androgenetic Alopecia Market was valued at USD 2.81 billion in 2023 and is projected to reach USD 5.76 billion by 2032, growing at a CAGR of 8.33% during the forecast period 2024–2032”
The androgenetic alopecia market is experiencing robust growth due to increasing aesthetic consciousness, early-onset baldness, and a rising preference for advanced pharmaceutical and topical therapies. While male pattern baldness remains the dominant cause, the market is witnessing a surge in demand for female-focused solutions, fueled by hormonal imbalances, urban stress, and evolving beauty norms.
Get a Sample Report of Androgenetic Alopecia Market@ https://www.snsinsider.com/sample-request/6848
In the United States, the market was valued at USD 0.84 billion in 2023 and is expected to double, reaching USD 1.67 billion by 2032. This growth is supported by widespread adoption of treatment solutions, elevated consumer spending on aesthetic healthcare, and a dense network of dermatology and trichology clinics catering to both men and women.
Major Players Analysis Listed in this Report are:
- Johnson & Johnson (Rogaine, Neutrogena T/Gel)
- Merck & Co., Inc. (Propecia, Proscar)
- Cipla Ltd. (Finpecia, Tugain Solution)
- Dr. Reddy’s Laboratories Ltd. (Mintop Forte, Finax)
- Sun Pharmaceutical Industries Ltd. (Alopex, Finabald)
- Hims & Hers Health, Inc. (Minoxidil Foam, Finasteride Tablets)
- AbbVie Inc. (Botox, Qilib Hair Regrowth System)
- Pfizer Inc. (Regaine, Xeljanz)
- Alpecin (Dr. Wolff Group) (Alpecin Caffeine Shampoo, Alpecin Liquid)
- L’Oréal S.A. (Serioxyl Denser Hair Serum, Aminexil Advanced)
- Lupin Pharmaceuticals, Inc. (Finpecia, Minoxidil Topical Solution)
- Intas Pharmaceuticals Ltd. (Morr 5%, Finast)
- Aclaris Therapeutics, Inc. (ATI-50001, ATI-502)
- Bayer AG (Minoxidil 5% Extra Strength, Pantogar Capsules)
- Follica, Inc. (Hair Follicle Neogenesis Device, Minoxidil-based Topical Therapy)
- Histogen Inc. (HST-001, Hair Stimulating Complex)
- Cellmid Limited (Evolis Professional Activate, Advangen Jo-Ju Shampoo)
- RepliCel Life Sciences Inc. (RCI-02, RCH-01)
- Vichy Laboratories (L’Oréal) (Dercos Aminexil Clinical 5, Dercos Energising Shampoo)
- Theradome Inc. (Theradome EVO LH40, Theradome PRO LH80)
Androgenetic Alopecia Market Report Scope
| Report Attributes | Details |
| Market Size in 2023 | USD 2.81 billion |
| Market Size by 2032 | USD 5.76 billion |
| CAGR (2024–2032) | 8.33% |
| U.S. Market 2023 | USD 0.84 billion |
| U.S. Forecast by 2032 | USD 1.67 billion |
| Base Year | 2023 |
| Forecast Period | 2024–2032 |
| Key Regional Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
Segment Analysis
By Gender:
The male market segment dominated the market in terms of revenue in 2023, which accounted for 58.42% of the global market. Dominance of men in the market is driven by the high incidence of male pattern baldness, early diagnosis, and social acceptance of hair regrowth treatment. -The female segment is expected to register the fastest growth as a result of rising awareness about hormonal hair loss, higher urban stress-induced hair fall, and the advent of topical and oral products that are gender specific.
By Treatment:
The pharmaceuticals segment dominated the market in 2023, contributing 97.16% of total revenues. This dominance stems from the widespread use of FDA-approved drugs like minoxidil and finasteride, as well as newer pipeline products under development. While surgical treatments are growing in popularity, pharmaceutical interventions remain the most accessible and cost-effective option.
By End-Use:
Dermatology clinics emerged as the leading end-use setting in 2023, holding a 72.26% market share. These clinics provide specialized consultations, customized regimens, and advanced technologies such as laser therapy, making them the preferred option for long-term care. However, online consultation platforms and home-use kits are gaining traction due to increased telehealth adoption.
By Sales Channel:
The prescriptions segment led the market in 2023 with a 66.08% share, driven by the reliance on physician-prescribed therapies and the need for continuous monitoring of drug efficacy and side effects. Nonetheless, over-the-counter and e-commerce sales are expanding rapidly, especially in urban Asia-Pacific and European markets.
For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ https://www.snsinsider.com/request-analyst/6848
Androgenetic Alopecia Market Segmentation
By Gender
- Male
- Female
By Treatment
- Pharmaceuticals
- Devices
By End-Use
- Dermatology Clinics
- Homecare Settings
By Sales Channel
- Prescriptions
- OTC
Regional Analysis
North America dominated the global androgenetic alopecia market in 2023, capturing 38.20% of total revenue. This is attributed to high disposable income, a well-established medical aesthetics industry, and strong awareness campaigns about hair loss treatments. Additionally, the presence of leading pharmaceutical companies and clinical research in the U.S. supports the robust growth in this region.
Meanwhile, the Asia Pacific region is expected to witness the fastest growth during the forecast period. Rapid urbanization, increased social media influence on appearance, and rising healthcare spending are key contributors. Countries like India, South Korea, and China are witnessing growing demand for affordable yet effective hair regrowth treatments and cosmetic dermatology services.
Recent Developments
- June 2023 – Dr. Reddy’s Laboratories Ltd. launched RgenX, a new generics division in India focused on affordable treatment options, including for androgenetic alopecia.
- December 2023 – Sun Pharmaceutical Industries Ltd. formed a strategic alliance with Aclaris Therapeutics to commercialize deuruxolitinib, a JAK inhibitor targeting alopecia-related conditions.
- February 2024 – Pfizer Inc. announced Phase 2 trial results for a novel topical JAK3 inhibitor intended for androgenetic alopecia.
Buy a Single-User PDF of Androgenetic Alopecia Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/6848
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
5.1 Patient Population & Gender-Specific Prevalence (2023)
5.2 Treatment Preference & Prescription Volume, by Region (2023)
5.3 OTC vs Prescription Sales Trends (2020–2032).
5.4 Expenditure Trends & Reimbursement Scenario, by Region (2023)
6. Competitive Landscape
7. Androgenetic Alopecia Market by Gender
8. Androgenetic Alopecia Market by Treatment
9. Androgenetic Alopecia Market by End-Use
10. Androgenetic Alopecia Market by Sales Channel
11. Regional Analysis
12. Company Profiles
13. Use Cases and Best Practices
14. Conclusion
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@snsinsider.com
